Drug resistance in malignant rhabdoid tumor cell lines

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2002-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00280-001-0398-yPMID 11862428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ADP‐ribosylation of oncogenic Ras proteins by Pseudomonas aeruginosa exoenzyme S in vivo

  1999cited by this paper
• Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors

  1999cited by this paper
• Functions of the MDM2 oncoprotein

  1999cited by this paper
• Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

  1999cited by this paper
• Successful treatment of a patient with stage IV rhabdoid tumor of the kidney: case report and review.

  1999cited by this paper
• Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer

  1998cited by this paper
• Five SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin (SMARC) genes are dispersed in the human genome.

  1998cited by this paper
• Establishment and molecular characterization of five cell lines derived from renal and extrarenal malignant rhabdoid tumors.

  1998cited by this paper
• Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs

  1998cited by this paper
• Genetics of Pediatric Central Nervous System Tumors

  1997cited by this paper
• Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

  1997cited by this paper
• p53; from inductive signal to cellular effect.

  1997cited by this paper
• Diversity and specialization of mammalian SWI/SNF complexes.

  1996cited by this paper
• Abnormal Centrosome Amplification in the Absence of p53

  1996cited by this paper
• The dual role of mutant p53 protein in chemosensitivity of human cancers.

  1996cited by this paper
• A p53-dependent mouse spindle checkpoint

  1995cited by this paper
• Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.

  1995cited by this paper
• Apoptosis, oncosis, and necrosis. An overview of cell death.

  1995cited by this paper
• Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5.

  1994cited by this paper
• p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.

  1994cited by this paper
• Doxorubicin-induced DNA degradation in murine thymocytes.

  1994cited by this paper
• Malignant rhabdoid tumor. A study with two established cell lines

  1993cited by this paper
• Topoisomerase inhibitors induce apoptosis in thymocytes.

  1993cited by this paper
• Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells.

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• p53 is required for radiation-induced apoptosis in mouse thymocytes

  1993cited by this paper
• Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.

  1993cited by this paper
• Modulation of a constitutive transcriptional block at exon-1 controls human c-myc oncogene expression.

  1990cited by this paper
• Rhabdoid Tumor of Kidney: A Report of 111 Cases from the National Wilms' Tumor Study Pathology Center

  1989cited by this paper
• Determination of cell number in monolayer cultures.

  1986cited by this paper
• Histopathology and prognosis of Wilms tumor Results from the first national wilms' tumor study

  1978cited by this paper

• Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma

  2017cites this paper
• A NOXA/MCL‐1 Imbalance Underlies Chemoresistance of Malignant Rhabdoid Tumor Cells

  2016cites this paper
• Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.

  2016cites this paper
• Malignant Rhabdoid Tumor of the Liver: A Case Report and Literature Review

  2015cites this paper
• All Children with Malignant Rhabdoid Tumors Should Be Treated Initially with Intensive Chemotherapy

  2015cites this paper
• Genetics and Genomics of Malignant Rhabdoid Tumours

  2014cites this paper
• Chromatin , Gene , and RNA Regulation SNF 5 Reexpression in Malignant Rhabdoid Tumors Regulates Transcription of Target Genes by Recruitment of SWI / SNF Complexes and RNAPII to the Transcription Start Site of Their Promoters

  2013cites this paper
• SNF5 Reexpression in Malignant Rhabdoid Tumors Regulates Transcription of Target Genes by Recruitment of SWI/SNF Complexes and RNAPII to the Transcription Start Site of Their Promoters

  2013cites this paper
• Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen

  2010cites this paper
• [Rhadboid tumours: hSNF/INI1 deficient cancers of early childhood with aggressive behaviour].

  2010cites this paper
• Les tumeurs rhabdoïdes : des tumeurs hSNF5/INI1-déficientes précoces et agressives

  2010cites this paper
• Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines

  2010cites this paper
• Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5+/−;p53+/− mice

  2009cites this paper
• Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival

  2009cites this paper
• Extra‐renal non‐cerebral rhabdoid tumours

  2008cites this paper
• Apoptosis in Hep2 cells treated with etoposide and colchicine.

  2004cites this paper
• Apoptotic response of malignant rhabdoid tumor cells

  2003cites this paper
• Tumor p53 status and response to topoisomerase II inhibitors.

  2003cites this paper